Poor
Partially Aligned
Patient Risk:
Low
Summary
The label supports identification of CIPRO as a ciprofloxacin product and documents multiple formulations and strengths, but it provides no information about pricing, insurance, generic availability, patents, pharmacy differences, substitution, or discount programs. Most claims are therefore unsupported by the supplied prescribing information.
Category Scores
Accurate Statements
Cipro is the brand name for ciprofloxacin.
Section 11 identifies CIPRO tablets and oral suspension as products containing ciprofloxacin or ciprofloxacin hydrochloride.
Unsupported Statements
Ciprofloxacin pricing can vary depending on the formulation, strength, quantity, insurance coverage, and pharmacy pricing.
The label identifies formulations and strengths but provides no pricing, insurance, quantity, or pharmacy-pricing information.
Different manufacturers may sell versions containing the same active ingredient, and their cash prices may differ even when the prescriptions are equivalent.
The label does not discuss manufacturers, equivalent prescriptions, or cash-price differences.
Ciprofloxacin is widely available as a generic in many strengths.
The label describes CIPRO tablet and suspension strengths but does not address generic availability or market distribution.
Generic ciprofloxacin generally costs less than on-patent brand drugs.
The label contains no information about generic pricing, patents, or comparative costs.
Out-of-pocket costs for ciprofloxacin depend on the specific generic product, local pharmacy rates, and use of a discount card.
The label does not discuss out-of-pocket costs, generic products, pharmacy rates, or discount cards.
The dosage strength, formulation, quantity, and dosing directions for ciprofloxacin can affect the dispensed package size and price.
Section 11 supports multiple formulations and strengths, but does not support the claims about quantity, dosing directions, package size, or price.
Ciprofloxacin is no longer available only as a brand-name drug.
The label does not discuss generic availability or whether ciprofloxacin is available as a brand-name product only.
Patent-driven pricing is usually less relevant for ciprofloxacin than for newer drugs.
The label contains no information about patents, drug age, or patent-driven pricing.
A lower-cost generic ciprofloxacin product may be substituted if the prescription allows substitution.
The label does not address generic substitution, prescription substitution rules, or relative cost.
Pharmacy discount programs or discount cards may reduce the cash price of ciprofloxacin.
The label contains no information about discount programs, discount cards, or cash prices.
Ciprofloxacin prices may differ between independent pharmacies, chain pharmacies, and mail-order pharmacies.
The label does not discuss pharmacy types or price differences.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response provides no treatment recommendation, dosing instruction, or safety advice. Its unsupported claims concern pricing and market availability rather than clinical use, so the immediate patient-safety risk is low.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most pricing, generic-market, patent, pharmacy, and discount-program claims are not addressed in the supplied prescribing information.
Suggested Improvement
Limit label-based claims to the product identity and the formulations and strengths described in Section 11, or explicitly state that pricing and availability information is outside the scope of the prescribing information.